- Home
- SYNA vs VKTX Comparison
SYNA vs VKTX Comparison
Compare SYNA & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SYNA | VKTX |
|---|---|---|
| Founded | 1986 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.0B |
| IPO Year | 2001 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SYNA | VKTX |
|---|---|---|
| Price | $101.76 | $33.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $100.78 | $95.86 |
| AVG Volume (30 Days) | 543.4K | ★ 6.0M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $663,588,000.00 | N/A |
| Revenue This Year | $12.63 | N/A |
| Revenue Next Year | $9.67 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 21.04 | N/A |
| 52 Week Low | $58.28 | $25.04 |
| 52 Week High | $149.11 | $43.15 |
Technical Indicators
Market Signals| Indicator | SYNA | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.40 | 50.28 |
| Support Level | $98.52 | $29.26 |
| Resistance Level | $101.06 | $35.47 |
| Average True Range (ATR) | 4.34 | 2.24 |
| MACD | 1.30 | 0.53 |
| Stochastic Oscillator | 81.43 | 38.10 |
Price Performance
Historical ComparisonAbout SYNA Synaptics Incorporated $0.001 Par Value
Synaptics Inc is a producer of semiconductor solutions for the mobile, PC, and Internet of Things markets. The company develops human interface solutions that enable touch, display, fingerprint, video, audio, voice, AI, and connectivity functions for smartphones, PCs, Internet of Things products, and other electronic devices. It operates in one segment: the development, marketing, and sale of semiconductor products used in electronic devices and products. The company geographically, it derives a majority of revenue from China, and also has its presence in Taiwan, Japan, South Korea, United States and Other countries.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.